可溶性鸟苷酸环化酶激动剂维利西呱的研究进展

Research progress on soluble guanylate cyclase activator vericiguat

一氧化氮(nitric oxide,NO)-可溶性鸟苷酸环化酶(soluble guanylate cyclase,sGC)-环磷酸鸟苷(cyclic guanosine monophosphate,cGMP)途径是一条与心血管疾病密切相关的信号通路,也是慢性心力衰竭(heart failure,HF)恶化以及HF治疗的潜在靶点。维利西呱(vericiguat)作为首个用于HF治疗的sGC激动剂,对sGC具有选择性强,不依赖于NO,直接刺激sGC使cGMP生成增多,通过恢复NO-sGC-cGMP信号通路保护多个靶器官,改善心功能及HF患者的临床预后。本文就维利西呱的研究进展作简要介绍。

Nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is a signaling pathway closely associated with cardiovascular disease,and is a potential target for the chronic heart failure (HF) deterioration and HF therapy.Vericiguat,as the first sGC stimulator used in the treatment of HF,has high selectivity for sGC,NO-independent capacity,directly stimulation of sGC to increase cGMP production,multiple target protection of organs through NO-sGC-cGMP signaling pathway restoration,heart function improvement and clinical prognosis of HF patients.This paper briefly introduced the recent research progress of vericiguat.